| Tresiba (insulin degludec) / Novo Nordisk |
ChiCTR2400081763: Efficacy and Safety of Insulin Degludec Injection in Chinese Patients with Type 2 Diabetes: A Multicenter, Randomized, Open-label, Parallel-group, Positive-controlled, Phase 3 Study |
|
|
| Completed | 3 | 360 | | Hui Sheng degludec insulin injection, treatment for 18 weeks; Originator insulin degludec injection (Tresiba), treatment for 18 weeks | Peking University People's Hospital; Hui Sheng Bio-pharmaceutical Co., Ltd., Sponsor | Type 2 Diabetes Mellitus | | | | |
2021-002569-16: Efficacy and Safety of the Once-Weekly Basal Insulin LY3209590 Therapy Compared with Daily Insulin Degludec in Adults with Type 2 Diabetes Treated with Basal Insulin |
|
|
| Ongoing | 3 | 939 | Europe | LY3209590, LY3209590, Solution for injection, Tresiba Flextouch | Eli Lilly and Company, Lilly S.A., Eli Lilly and Company | type 2 diabetes mellitus Diabetes mellitus 2. typu, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-005891-21: Efficacy and Safety of LY3209590 Compared to Degludec in Adults with Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Not yet recruiting | 3 | 888 | Europe | LY3209590, LY3209590, Solution for injection in pre-filled pen, Tresiba Flextouch | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-005892-38: Efficacy and Safety of LY3209590 Compared with Insulin Degludec in Participants with Type 1 Diabetes Treated with Multiple Daily Injection Therapy |
|
|
| Not yet recruiting | 3 | 670 | Europe | LY3209590, LY3209590, Solution for injection in pre-filled pen, Tresiba Flextouch | Eli Lilly and Company, Eli Lilly and Company | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 1 Cukrovka 1. typu, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 09/24 | 04/25 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
| Completed | 3 | 986 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes | 05/24 | 05/24 | | |
NCT05641337: Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes |
|
|
| Recruiting | 3 | 184 | RoW | Insulin Degludec and Insulin Aspart, metformin, linagliptin | Huashan Hospital | Liver Cirrhosis, Diabetes | 12/25 | 12/25 | | |
| Recruiting | 3 | 344 | RoW | Insulin degludec injection, Tresiba® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/25 | 12/25 | | |
